10-K · March 30, 2026
INmune Bio is a clinical‑stage biotech focused on reprogramming innate immunity, with lead asset CORDStrom completing a pivotal blinded randomized cross‑over trial and the company targeting MAA filings in the UK/EU…
Earnings analysis · 10-Q
INMB earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
INmune Bio's Q4 2026 results showed no reported revenue, following a previous quarter revenue of $50,000. The company reported a reduced net loss of $5.4 million compared to a loss of $9.7 million in the same quarter…
Read full summary
INmune Bio's Q4 2026 results showed no reported revenue, following a previous quarter revenue of $50,000. The company reported a reduced net loss of $5.4 million compared to a loss of $9.7 million in the same quarter last year, indicating improved cost management and lower research expenses.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.18
What stood out
-
Improved EPS Over Prior Year
Diluted EPS improved to -$0.18 from -$0.24 a year ago, reflecting a positive trend.
-
Reduction in Operating Expenses
Total operating expenses decreased to $5.8 million from $9.95 million in the prior year, a reduction of $4.14 million.
-
Higher Cash Balance
Cash and cash equivalents stood at $21.4 million, down from $24.8 million at the end of 2025, indicating a manageable liquidity position.
-
Lower Research and Development Costs
R&D expenses dropped significantly to $3.641 million from $7.639 million year-over-year, due to completion of certain trials.
-
Increase in Other Income
Other income increased to $0.4 million for Q1 2026, compared to $0.2 million in Q1 2025, suggesting better financial management.
-
Sustained Operational Improvements
Net cash used in operating activities decreased to $3.4 million from $6.8 million year-on-year.
What to watch
-
Ongoing Losses Concerning
Net loss of $5.4 million indicates continuing operational struggles despite progress.
-
Capital Requirement Risks
Substantial doubt regarding ability to continue as a going concern due to anticipated losses and funding needs is emphasized.
-
Regulatory Approval Dependencies
Continued delays or failures in receiving regulatory approvals for products could significantly impact future revenues.
Management's outlook
Management suggests continued losses will persist; future financial condition remains uncertain.
Earlier filings 4
10-Q · August 7, 2025
INmune Bio's Q2 2025 results reveal significant continued losses, with actual revenue reported at $0.0 and a net loss of $24.5 million, resulting in a diluted EPS of -$1.05, down from -$0.50 in Q2 2024. Cash reserves…
10-Q · October 31, 2024
INmune Bio reported Q3 2024 net loss of $12,093,000 (‑$0.60/share) on revenue of $0, widening from Q3 2023 net loss of $8,563,000 (‑$0.48/share). R&D spending accelerated to $10,067,000 in the quarter (vs. $5,985,000…
10-Q · November 1, 2023
INmune Bio reported Q3 revenue of $43,000 (down from $98,000 in Q3 2022) and GAAP net loss of $8,563,000 (EPS $(0.48)) for the quarter. Operating expenses increased to $8,571,000 in the quarter, cash declined to…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.